BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 33984267)

  • 1. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
    Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
    Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.
    Lim CT; Tan KW; Wu M; Ulferts R; Armstrong LA; Ozono E; Drury LS; Milligan JC; Zeisner TU; Zeng J; Weissmann F; Canal B; Bineva-Todd G; Howell M; O'Reilly N; Beale R; Kulathu Y; Labib K; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2517-2531. PubMed ID: 34198325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
    Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
    J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
    Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
    EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
    Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compounds derived from Humulus lupulus inhibit SARS-CoV-2 papain-like protease and virus replication.
    Herzog AM; Göbel K; Marongiu L; Ruetalo N; Alonso MC; Leischner C; Busch C; Burkard M; Lauer UM; Geurink PP; Knobeloch KP; Schindler M; Fritz G; Venturelli S
    Phytomedicine; 2024 Jan; 123():155176. PubMed ID: 37976697
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Alesawy MS; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34771004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
    Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
    Elife; 2021 Oct; 10():. PubMed ID: 34617885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
    Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
    Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study.
    ElNaggar MH; Abdelwahab GM; Kutkat O; GabAllah M; Ali MA; El-Metwally MEA; Sayed AM; Abdelmohsen UR; Khalil AT
    Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323478
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.